| 000 | 01021 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250515172516.0 | ||
| 264 | 0 | _c20090709 | |
| 008 | 200907s 0 0 eng d | ||
| 022 | _a1099-1069 | ||
| 024 | 7 |
_a10.1002/hon.909 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGriesshammer, Martin | |
| 245 | 0 | 0 |
_aDefining targets in myeloproliferative disorders: reflecting on what is important. _h[electronic resource] |
| 260 |
_bHematological oncology _cJun 2009 |
||
| 300 |
_a2-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMyeloproliferative Disorders _xclassification |
| 650 | 0 | 4 | _aPlatelet Count |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xdiagnosis |
| 650 | 0 | 4 | _aWorld Health Organization |
| 773 | 0 |
_tHematological oncology _gvol. 27 Suppl 1 _gp. 2-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hon.909 _zAvailable from publisher's website |
| 999 |
_c18894798 _d18894798 |
||